- Home
- SRFM vs PEPG Comparison
SRFM vs PEPG Comparison
Compare SRFM & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- PEPG
- Stock Information
- Founded
- SRFM 2011
- PEPG 2018
- Country
- SRFM United States
- PEPG United States
- Employees
- SRFM N/A
- PEPG N/A
- Industry
- SRFM Transportation Services
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- SRFM Consumer Discretionary
- PEPG Health Care
- Exchange
- SRFM Nasdaq
- PEPG Nasdaq
- Market Cap
- SRFM 58.2M
- PEPG 52.4M
- IPO Year
- SRFM 2023
- PEPG 2022
- Fundamental
- Price
- SRFM $2.33
- PEPG $1.46
- Analyst Decision
- SRFM Strong Buy
- PEPG Buy
- Analyst Count
- SRFM 3
- PEPG 3
- Target Price
- SRFM $6.02
- PEPG $7.67
- AVG Volume (30 Days)
- SRFM 281.5K
- PEPG 224.5K
- Earning Date
- SRFM 05-13-2025
- PEPG 05-08-2025
- Dividend Yield
- SRFM N/A
- PEPG N/A
- EPS Growth
- SRFM N/A
- PEPG N/A
- EPS
- SRFM N/A
- PEPG N/A
- Revenue
- SRFM $112,307,000.00
- PEPG N/A
- Revenue This Year
- SRFM N/A
- PEPG N/A
- Revenue Next Year
- SRFM $45.73
- PEPG N/A
- P/E Ratio
- SRFM N/A
- PEPG N/A
- Revenue Growth
- SRFM 31.17
- PEPG N/A
- 52 Week Low
- SRFM $0.90
- PEPG $0.88
- 52 Week High
- SRFM $6.72
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- SRFM 42.26
- PEPG 48.32
- Support Level
- SRFM $2.36
- PEPG $1.40
- Resistance Level
- SRFM $2.85
- PEPG $1.73
- Average True Range (ATR)
- SRFM 0.22
- PEPG 0.17
- MACD
- SRFM -0.01
- PEPG 0.01
- Stochastic Oscillator
- SRFM 7.69
- PEPG 32.50
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.